Shopping Cart
Remove All
Your shopping cart is currently empty
Vamorolone (VBP15) is an orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone displays effective NF-κB inhibition and substantially decreases hormonal effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | In Stock | In Stock | |
| 2 mg | $44 | In Stock | In Stock | |
| 5 mg | $72 | In Stock | In Stock | |
| 10 mg | $113 | In Stock | In Stock | |
| 25 mg | $198 | In Stock | In Stock | |
| 50 mg | $313 | In Stock | In Stock | |
| 100 mg | $468 | In Stock | In Stock | |
| 200 mg | $673 | Backorder | Backorder | |
| 1 mL x 10 mM (in DMSO) | $79 | In Stock | In Stock |
| Description | Vamorolone (VBP15) is an orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone displays effective NF-κB inhibition and substantially decreases hormonal effects. |
| In vitro | Vamorolone is a first-in-class mineralocorticoid receptor antagonist/dissociative glucocorticoid receptor ligand. Vamorolone inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor and mineralocorticoid receptor. Vamorolone (0.1, 1μM; 30 minutes) decreases the production of IL1βand CCL5 inflammatory mediators in primary human macrophages [1][2][3]. |
| In vivo | Vamorolone (30 mg/kg; p.o.; daily for 20 days) decreases CNS Inflammation in murine experimental autoimmune encephalomyelitis. Vamorolone (5-30 mg/kg; cherry syrup) displays a superior side effect profile compared to pharmacological glucocorticoids in mdx mice [1][2]. |
| Synonyms | VBP15 |
| Molecular Weight | 356.46 |
| Formula | C22H28O4 |
| Cas No. | 13209-41-1 |
| Smiles | [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |
| Relative Density. | 1.24 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 62.5 mg/mL (175.34 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.